Belysse Group Nv · EURONEXT:BELYS
Belysse Group Nv — H1 2024 Earnings Presentation
15 slides from Belysse Group Nv's earnings presentation, Aug 23, 2024
Slide 1: H1 2024 Results
H1 2024 Results BELYSSE jtC modulyss § Clercedition BENTLEY:
Slide 2: Disclaimer
Disclaimer In considering any performance information contained herein, you should bear in mind that past or projected performance is not necessarily indicative of future results, and there can be no assurance that any entity referenced herein will achieve comparable results or that illustrative ret
Slide 3: Introduction
Introduction H] 2024 Financial Summary Financial Review Beyond Update Conclusion Q&A aOR ON oo James Neuling Andy Rogiest Ruben Pattheeuws Chief Executive Officer Chief Financial Officer Group Director of Sustainability and Strategic Projects
Slide 4: H1 2024 Financial Summary
H1 2024 Financial Summary 75.1% YoY Adj. EBITDA growth 3.2x Leverage Excluding IFRS16 75.1% organic 0.0% FX impact HI Net Debt €139.2M H1 2024 Consolidated Adjusted EBITDA of €21.5 - US €14.4m + Europe €7.1m Leverage stands at 3.2x at the end of H1 2024 Net Debt includes €25.3m impact from IFRS 16 l
Slide 5: Financial Review
Financial Review
Slide 6: Q2 2024 Group Revenue
@2 2024 Group Revenue em 79.0 (3.7) . (0.8) 74.5 Revenue Q2 2023 Europe US Revenue Q2 2024 (10.4)% (1.9)% Organic FX Impact Reported 2Q24 consolidated revenue was €74.5m (5.7% YoY). In US, revenue decreased by 1.9% to €42.7m compared to last year. Volumes in the US improved compared to 1924, led by
Slide 7: H1 2024 Group Revenue
H1 2024 Group Revenue ém 155.6 (5.9) (5.0) 144.7 — Revenue H1 2023 Europe US Revenue H1 2024 (7.8)% (6.2)% HI Growth (€m) Organic (10.9) FX Impact (0.0) 0.0% Reported (10.9) (7.0)% 1H24 consolidated revenue was €144.7m (7.0% YoY). In US, revenue decreased by 6.2% versus last year to €75.9m, mainly d
Slide 8: H1 2024 Group Adjusted EBITDA
€m H1] 2024 Group Adjusted EBITDA Adj. EBITDA Margin (9%) 9.3 0.0 21.5 12.2 75.1%, 0.0% 75.1% EBITDA H1 2023 Growth FX Impact. EBITDA Hi 2024 Europe 7 (1.6) Us 14.4 13.9 3.6% Consolidated Adjusted EBITDA 21.5 12.2 75.1% * 1H24 Adjusted EBITDA was €21.5m (+75.1% YoY) with an Adjusted EBITDA margin of
Slide 9: H1 2024 Cash Flow
H1 2024 Cash Flow €m 21.5 * The cash outflow of €6.8m in 1H24 was mainly (29) driven by debt repayments, interest payments and (4.1) (09) arrangement fees linked to the refinancing (-€15.1m), (62) Capex -€5.2m, Changes in Other working capital of 35.8 -€4.1m (mainly 2023 bonuses and rebates settleme
Slide 10: Leverage stands at 3.2x, excluding IFRS lease liabilities
Leverage! stands at 3.2x, excluding IFRS 16 lease liabilities €m cesh EE Ea LTM Adj. Cash EBITDA 351 44 157 466 156 157 158 148 isi 145 29 34 31 30 we 30 32 29 27 132 = 5.5x 22 127 123 — 126 5.2x = 127 118 46x 122 aie 3.8x 3.7% 1/22 qi/22 02/22 3/22 4/22 1/23 02/23 03/23 94/23 H1/24 Actual Profarma
Slide 11: BEYOND update
BEYOND update
Slide 12: Sustainability through Innovation
Sustainability through Innovation € cradletocradie * Total CO2 emission per m’ produced has been reduced by 13% compared to 2018. * Energy efficiency initiatives continue to deliver impact through lower gas and electricity consumption, while additional energy savings initiatives have been implemente
Slide 13: Our Lean program has delivered €0.7m savings in H1 2024
Our Lean program has delivered €0.7m savings in H1 2024, exceeding the plan by 15% As areminder: objective of this Lean program is to deliver €8m cumulative savings over a 4-year period (2022 — 2025). H1 2024 results amount to €0.7m P&L savings vs. 2023, against a target of €0.6m. From the start in
Slide 14: Conclusion
Conclusion 1H24 Consolidated Revenue was €144.7m and Adjusted EBITDA was €21.5m, resulting in an Adjusted EBITDA margin of 14.8%. Consolidated Group Revenue for 1H24 reflects continued lower market demand in the European Residential business line as well as softer project-driven demand in the US in
Slide 15: Q3 2024 Update in October 2024
Q3 2024 g Update in October 2024